Literature DB >> 12693778

Application of a ketogenic diet in children with autistic behavior: pilot study.

Athanasios Evangeliou1, Ioannis Vlachonikolis, Helen Mihailidou, Martha Spilioti, Astrinia Skarpalezou, Nikolaos Makaronas, Ahilleas Prokopiou, Panagiotis Christodoulou, Georgia Liapi-Adamidou, Emmanouel Helidonis, Stylianos Sbyrakis, Jan Smeitink.   

Abstract

A pilot prospective follow-up study of the role of the ketogenic diet was carried out on 30 children, aged between 4 and 10 years, with autistic behavior. The diet was applied for 6 months, with continuous administration for 4 weeks, interrupted by 2-week diet-free intervals. Seven patients could not tolerate the diet, whereas five other patients adhered to the diet for 1 to 2 months and then discontinued it. Of the remaining group who adhered to the diet, 18 of 30 children (60%), improvement was recorded in several parameters and in accordance with the Childhood Autism Rating Scale. Significant improvement (> 12 units of the Childhood Autism Rating Scale) was recorded in two patients (pre-Scale: 35.00 +/- 1.41[mean +/- SD]), average improvement (> 8-12 units) in eight patients (pre-Scale: 41.88 +/- 3.14[mean +/- SD]), and minor improvement (2-8 units) in eight patients (pre-Scale: 45.25 +/- 2.76 [mean +/- SD]). Although these data are very preliminary, there is some evidence that the ketogenic diet may be used in autistic behavior as an additional or alternative therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12693778     DOI: 10.1177/08830738030180020501

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  71 in total

Review 1.  A review of low-carbohydrate ketogenic diets.

Authors:  Eric C Westman; John Mavropoulos; William S Yancy; Jeff S Volek
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

Review 2.  State of the ketogenic diet(s) in epilepsy.

Authors:  Jennifer Huffman; Eric H Kossoff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

Review 3.  Ketogenic diet in migraine: rationale, findings and perspectives.

Authors:  Piero Barbanti; Luisa Fofi; Cinzia Aurilia; Gabriella Egeo; Massimiliano Caprio
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

Review 4.  Are therapeutic diets an emerging additional choice in autism spectrum disorder management?

Authors:  M Gogou; G Kolios
Journal:  World J Pediatr       Date:  2018-05-30       Impact factor: 2.764

Review 5.  Adenosine and autism: a spectrum of opportunities.

Authors:  Susan A Masino; Masahito Kawamura; Jessica L Cote; Rebecca B Williams; David N Ruskin
Journal:  Neuropharmacology       Date:  2012-08-24       Impact factor: 5.250

6.  Dietary therapies for epilepsy and other neurological disorders: highlights of the 3rd international symposium.

Authors:  Carl E Stafstrom
Journal:  Epilepsy Curr       Date:  2013-03       Impact factor: 7.500

7.  Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study.

Authors:  Moran Artzi; Gilad Liberman; Nachum Vaisman; Felix Bokstein; Faina Vitinshtein; Orna Aizenstein; Dafna Ben Bashat
Journal:  J Neurooncol       Date:  2017-01-10       Impact factor: 4.130

8.  The ketogenic diet: uses in epilepsy and other neurologic illnesses.

Authors:  Kristin W Barañano; Adam L Hartman
Journal:  Curr Treat Options Neurol       Date:  2008-11       Impact factor: 3.598

9.  Consumption of a high-fat diet in adulthood ameliorates the effects of neonatal parathion exposure on acetylcholine systems in rat brain regions.

Authors:  Theodore A Slotkin; T Leon Lassiter; Ian T Ryde; Nicola Wrench; Edward D Levin; Frederic J Seidler
Journal:  Environ Health Perspect       Date:  2009-02-03       Impact factor: 9.031

10.  Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity.

Authors:  S A Masino; M Kawamura; C D Wasser; C A Wasser; L T Pomeroy; D N Ruskin
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.